Studies assessing the levels of CK18 fragments in liver disease in the pediatric population focused mainly on NAFLD, which confirmed CK18 as a promising noninvasive marker of fibrosis [16,17]. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatotic liver disease.